Please assess the completion status of the following clinical trial:

Trial Title: Bone Wax Use for Hemostasis During Primary Unilateral Total Knee Arthroplasty

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients scheduled for primary unilateral total knee arthroplasty~2. Preoperative Hemoglobin \>11mg/dL~3. Preoperative platelet count of \>150,000~Exclusion Criteria:~1. Patients unable to take aspirin or apixaban for VTE prophylaxis~2. Allergy to any of the ingredients in bone wax (beeswax, paraffin, or isopropyl palmitate)~3. Patients taking clopidogrel (Plavix), ticagrelor (Brilinta), or prasugrel (Effient) or any other antiplatelet medication (except for aspirin 81 mg)~4. Patients unable to get IV Tranexamic Acid for any reason~5. Patients requiring anticoagulant treatment prior to surgery

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment arm (Type: ACTIVE_COMPARATOR): This arm will have bone wax applied to the exposed cancellous surfaces of the bone.
- Control Arm (Type: NO_INTERVENTION): This arm will serve as the control group. Bone wax will not be used in this group.

Based on this trial design, predict the completion outcome and termination type (if applicable).